Cis‐platin and Methotrexate in the Treatment of Transitional Cell Carcinoma of the Urinary Tract
- 1 June 1985
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 57 (3), 299-302
- https://doi.org/10.1111/j.1464-410x.1985.tb06348.x
Abstract
Summary— Nineteen patients with recurrent or metastatic transitional cell carcinoma of the urinary tract were treated with a 3-weekly combination of methotrexate 200 mg/m2 as a 24-h infusion with folinic acid rescue and cis-platin 100 mg/m2. An objective response rate of 68% was obtained, with 4 patients (21 %) achieving complete remission. Pulmonary disease and lymph node metastases were particularly sensitive to this therapy. The median duration of response was 21 weeks with a median survival of 54 weeks in the responding patients. This regimen warrants further investigation in the treatment of invasive bladder carcinoma.This publication has 5 references indexed in Scilit:
- The treatment of advanced bladder cancer with methotrexate and cis-platinum—a pharmacokinetic studyEuropean Journal of Cancer and Clinical Oncology, 1984
- Experimental studies on the radiation-modifying effect of cis-diamminedichloroplatinum II (DDP) in human bladder transitional cell carcinomas grown in nude miceCancer, 1983
- Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancerCancer, 1981
- The Treatment of Advanced Bladder Cancer with MethotrexateBritish Journal of Urology, 1977
- CIS-DICHLORODIAMMINEPLATINUM(II) IN ADVANCED BLADDER CANCER1976